Mechanism of action
From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
|back to top|
FLAM: FLavopiridol (Alvocidib), Ara-C (Cytarabine), Mitoxantrone
|Zeidner et al. 2015 (JHOC-J1101)||Randomized Phase II (E)||7+3d, high-dose dauno||Superior CR rate|
- Alvocidib (Flavopiridol) 50 mg/m2 IV once per day on days 1 to 3
- Cytarabine (Cytosar) 667 mg/m2/day IV continuous infusion on days 6 to 8 (total dose: 2000 mg/m2)
- Mitoxantrone (Novantrone) 40 mg/m2 IV once on day 9
- JHOC-J1101: Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. link to original article contains verified protocol link to PMC article PubMed
History of changes in FDA indication
- 4/13/2007: Granted orphan status for treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.
- 4/23/2014: Granted orphan designation for the treatment of patients with acute myeloid leukemia (AML)
Also known as
- Code names: HMR 1275, L-868275